This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Herpes simplex virus (HSV)	HSV glycoprotein B	Mouse studies suggest the mAb hu2c could prevent or treat drug-resistant HSV infections. In an immunodeficient mouse model for HSV-1 infection, 15 mg/kg of systemically delivered hu2c, a humanized mAb targeting HSV glycoprotein B, protected mice from viral challenge and led to clearance of virus in pre-established infection. In immunodeficient mice infected with a multidrug-resistant strain of HSV-1, hu2c completely cleared the virus in seven of eight mice, whereas acyclovir had only minor effects on viral load. Ongoing work includes tests of hu2c in HSV-2–infected animals and clinical development of the antibody.	Patent application filed; available for licensing	Krawczyk, A. *et al. Proc. Natl. Acad. Sci. USA*; published online April 8, 2013; doi:10.1073/pnas.1220019110 **Contact:** Jürgen Krauss, Heidelberg University Medical Center, Heidelberg, Germany e-mail: juergen.krauss@nct-heidelberg.de

SciBX 6(15); doi:10.1038/scibx.2013.365
Published online April 18, 2013